HK1060520A1 - Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus - Google Patents

Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus

Info

Publication number
HK1060520A1
HK1060520A1 HK04103556.6A HK04103556A HK1060520A1 HK 1060520 A1 HK1060520 A1 HK 1060520A1 HK 04103556 A HK04103556 A HK 04103556A HK 1060520 A1 HK1060520 A1 HK 1060520A1
Authority
HK
Hong Kong
Prior art keywords
reovirus
sensitization
chemotherapeutic agent
neoplastic cells
agent resistant
Prior art date
Application number
HK04103556.6A
Other languages
English (en)
Inventor
Matthew C Coffey
Bradley G Thompson
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of HK1060520A1 publication Critical patent/HK1060520A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK04103556.6A 2001-02-20 2004-05-19 Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus HK1060520A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27036301P 2001-02-20 2001-02-20
PCT/CA2002/000201 WO2002066040A2 (en) 2001-02-20 2002-02-19 Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus

Publications (1)

Publication Number Publication Date
HK1060520A1 true HK1060520A1 (en) 2004-08-13

Family

ID=23031034

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04103556.6A HK1060520A1 (en) 2001-02-20 2004-05-19 Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus

Country Status (16)

Country Link
US (5) US7264798B2 (es)
EP (2) EP1361884B1 (es)
JP (3) JP4951194B2 (es)
AR (1) AR035227A1 (es)
AT (1) ATE516807T1 (es)
AU (2) AU2002234453B2 (es)
BR (1) BR0207691A (es)
CA (1) CA2437468C (es)
DK (1) DK1361884T3 (es)
ES (1) ES2367768T3 (es)
HK (1) HK1060520A1 (es)
IL (2) IL157167A0 (es)
MX (1) MXPA03007486A (es)
NZ (2) NZ537709A (es)
WO (1) WO2002066040A2 (es)
ZA (1) ZA200305875B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
AR035227A1 (es) 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
WO2003094939A1 (en) * 2002-05-10 2003-11-20 Oncolytics Biotech Inc. Sensitization of neoplastic cells to radiation therapy with oncolytic viruses
CA2522711A1 (en) * 2003-04-25 2004-11-11 Wellstat Biologics Corporation Treating hepatocellular carcinomas using therapeutic viruses
DE602004018927D1 (de) 2003-06-18 2009-02-26 Genelux Corp Modifizierte rekombinante vacciniaviren, verwendungen davon
CN1946421B (zh) * 2004-04-27 2013-07-17 威尔斯达特生物制剂公司 使用病毒和喜树碱进行的癌症治疗
WO2005112966A1 (en) * 2004-05-21 2005-12-01 Orison Biotechnology Inc. Combined therapy with a herbal extract and a reovirus for killing neoplastic cells in a subject
RU2435586C2 (ru) * 2005-07-14 2011-12-10 Веллстат Байолоджикс Корпорейшн Лечение рака с применением вирусов, фторпиримидинов и камптотецинов
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
WO2007099401A2 (en) * 2005-08-01 2007-09-07 University Technologies International, Inc. Oncolytic attenuated reoviruses for treatment of proliferative disorders
DE602006010902D1 (de) * 2005-11-24 2010-01-14 Aicuris Gmbh & Co Kg Parapocken-viren in kombination mit klassischen zytotoxischen chemotherapeutika als biochemotherapie zur behandlung von krebs
US8052968B2 (en) 2006-10-16 2011-11-08 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
WO2008150496A2 (en) * 2007-05-31 2008-12-11 Genelux Corporation Assay for sensitivity to chemotherapeutic agents
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
JP2010533718A (ja) * 2007-07-18 2010-10-28 ジェネラックス・コーポレイション 腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用
JP2011500608A (ja) * 2007-10-22 2011-01-06 オンコリティクス バイオテク，インコーポレーテッド 増殖性障害の治療レジメン
AU2009210654A1 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and bevacizumab to treat colorectal cancer
EP2300023A2 (en) * 2008-05-16 2011-03-30 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
KR101585702B1 (ko) * 2008-05-22 2016-01-15 제일약품주식회사 종양파괴 바이러스 요법에 대한 과다증식성 세포의 종양 억제인자-기초된 민감성
JP2011520994A (ja) * 2008-05-27 2011-07-21 オンコリティクス バイオテク，インコーポレーテッド 腫瘍崩解性レオウイルス療法中の炎症性サイトカイン産生の排除
TW200951143A (en) * 2008-05-27 2009-12-16 Oncolytics Biotech Inc Modulating interstitial pressure and oncolytic viral delivery and distribution
WO2013163724A1 (en) * 2012-04-30 2013-11-07 Oncolytics Biotech Inc. Protecting modified viruses from neutralizing antibodies using the reovirus sigma 1 protein
EP3209382B1 (en) 2014-10-24 2020-11-25 Calidi Biotherapeutics, Inc. Combination immunotherapy approach for treatment of cancer
CN104881181B (zh) * 2015-05-27 2019-07-26 联想(北京)有限公司 显示方法及电子设备
EP3876951A1 (en) 2018-11-06 2021-09-15 Calidi Biotherapeutics, Inc. Enhanced systems for cell-mediated oncolytic viral therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU682854B2 (en) 1993-02-16 1997-10-23 Onyx Pharmaceuticals Cytopathic viruses for therapy and prophylaxis of neoplasia
DK1314431T3 (da) 1993-04-30 2008-11-10 Wellstat Biologics Corp Oprensede sammensætninger af Newcastle disease virus
US5776743A (en) 1994-09-06 1998-07-07 La Jolla Cancer Research Foundation Method of sensitizing tumor cells with adenovirus E1A
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
NZ518945A (en) 1997-10-09 2007-03-30 Wellstat Biologics Corp Treatment of neoplasms with viruses
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
AU782020B2 (en) * 1999-11-12 2005-06-30 Oncolytics Biotech, Inc. Viruses for the treatment of cellular proliferative disorders
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders

Also Published As

Publication number Publication date
JP2004517966A (ja) 2004-06-17
US7964187B2 (en) 2011-06-21
BR0207691A (pt) 2006-01-31
WO2002066040A8 (en) 2003-03-20
JP2008120837A (ja) 2008-05-29
ATE516807T1 (de) 2011-08-15
CA2437468C (en) 2007-06-19
IL157167A (en) 2014-05-28
NZ527399A (en) 2005-09-30
US7608257B2 (en) 2009-10-27
IL157167A0 (en) 2004-02-08
US20080031851A1 (en) 2008-02-07
JP4951194B2 (ja) 2012-06-13
DK1361884T3 (da) 2011-10-03
US20130017172A1 (en) 2013-01-17
CA2437468A1 (en) 2002-08-29
MXPA03007486A (es) 2003-12-08
US8658158B2 (en) 2014-02-25
AR035227A1 (es) 2004-05-05
EP1361884A2 (en) 2003-11-19
AU2002234453B2 (en) 2007-05-17
US20100021432A1 (en) 2010-01-28
NZ537709A (en) 2006-11-30
US20020168344A1 (en) 2002-11-14
EP2314301A3 (en) 2011-08-17
EP2314301A2 (en) 2011-04-27
JP2012072192A (ja) 2012-04-12
AU2007207860B2 (en) 2008-10-23
US20110243890A1 (en) 2011-10-06
ES2367768T3 (es) 2011-11-08
US7264798B2 (en) 2007-09-04
WO2002066040A2 (en) 2002-08-29
EP1361884B1 (en) 2011-07-20
WO2002066040A3 (en) 2003-05-30
AU2007207860A1 (en) 2007-09-06
ZA200305875B (en) 2004-07-30

Similar Documents

Publication Publication Date Title
IL157167A0 (en) Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus
DK1381339T3 (da) Tampon med spiralformede riller
EP1421057A4 (en) CHEMOTHERAPEUTIC AGENTS
AU2003275140A8 (en) Theree-dimensional construct for the design and fabrication of physiological fluidic networks
MX2019010879A (es) Tratamiento de cancer.
HK1051600A1 (en) Memory cell structure
HUP0401534A3 (en) Modified factor ix
GB0120273D0 (en) Floating verticle-axis turbine
SG108876A1 (en) Multiple hydroprocessing reactors with intermediate flash zones
IL160772A0 (en) Pancreatic smal cells and uses thereof
AU2002301545A1 (en) Multiple hydroprocessing reactors with intermediate flash zones
GB0127033D0 (en) Stent manufacture
HUP0600238A2 (en) Benzothiazole- and benzoxazole-4,7-dione derivatives and their use
DE60030708D1 (de) Beschichtete Hartmetallkörper
AU144209S (en) Pocket lamp
EP1412320A4 (en) BONDED CYCLITOLS AND THEIR POLYSULFATE DERIVATIVES
GB2347802B (en) Gas discharge lamp
CA93349S (en) Pocket lamp
TW506631U (en) Composing structure of spiral antenna
GB0126000D0 (en) Use of 4ñ Phorbol
TW527019U (en) Improved structure of cubic cell
TW576493U (en) Improved lamp body structure
GB0119757D0 (en) Long-term selective inhibition of cellular and viral genes
TW450340U (en) Water lamp structure with inner and outer tubes
GB0113597D0 (en) Inflatable with memory retention

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20220218